STOCK TITAN
  1. Home
  2. News
  3. SLP

Simulations Plus, Inc. - SLP STOCK NEWS

Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.

Simulations Plus, Inc. (NASDAQ: SLP) is a leading developer of modeling and simulation software and consulting services that support drug discovery, development research, and regulatory submissions. The company collaborates with pharmaceutical organizations to implement a data-driven, strategic modeling methodology that begins in early discovery stages, extends through preclinical and clinical development, and continues into clinical trials and post-approval phases.

Simulations Plus, through its subsidiaries Cognigen Corporation and DILIsym Services, offers a suite of top-ranked, user-friendly software solutions. These include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more. These tools bridge data mining and compound library screening with QSAR models and PBPK/TK modeling and simulation in both animals and humans. The company's quantitative systems pharmacology approaches are widely recognized and licensed by regulatory agencies globally.

In addition to software development, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. The company’s operations are divided into two primary segments: software and services. The software segment generates the majority of the company’s revenue.

Over the past 20 years, Simulations Plus has consistently partnered with clients to reduce costs and accelerate research timelines. The company’s innovative technology and methodologies have earned it a reputation as a reliable partner in the pharmaceutical industry.

Latest News: Simulations Plus continues to make headlines with its innovative solutions and strategic partnerships. Stay updated with the latest developments and achievements of Simulations Plus on our news section.

News

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Rhea-AI Summary
Simulations Plus extends agreement with NIEHS for research project on chemical safety assessment utilizing computational tools like ADMET Predictor and GastroPlus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
News

Simulations Plus Launches Corporate Development Initiative

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces a strategic shift towards investing in early-stage companies to drive innovation and collaboration. The company aims to enhance innovation, grow its M&A pipeline, expand revenue opportunities, and drive shareholder returns through strategic investments and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
none
-
News

Simulations Plus to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary
Simulations Plus, Inc. (SLP) will participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference virtually from February 13-14, 2024. CEO Shawn O’Connor will present on February 13 at 11:20 a.m. Eastern Time. The live webcast will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
News

Simulations Plus Releases GastroPlus® Version 9.9

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces the release of GastroPlus® 9.9, featuring expanded models for ocular, oral cavity, and dermal delivery routes, improved Biologics Module, and upgraded ADMET Predictor® version 11 models. The company collaborated with the FDA and other regulatory agencies, incorporating feedback from over 100 companies to enhance the software. The updates aim to improve the functionality and predictive capabilities of the platform, supporting program design and regulatory submissions for pharmaceutical industry and clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
News

Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant

Rhea-AI Summary
Simulations Plus, Inc. (SLP) has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA) to aid in the understanding of oral modified-release (MR) formulations and advance the development and approval of generic oral MR drug products through a joint proposal with Northeastern University and The TIM Company. The project will integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
News

Simulations Plus Reports First Quarter Fiscal 2024 Financial Results

Rhea-AI Summary
Simulations Plus, Inc. (NASDAQ: SLP) reported Q1 fiscal 2024 financial results, with total revenue of $14.5 million, a 21% increase. Software revenue increased 25% to $7.6 million, and services revenue increased 17% to $6.9 million. Adjusted EBITDA was $3.4 million, and net income was $1.9 million with diluted EPS of $0.10. The company maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
earnings
News

Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces key leadership changes effective January 3, 2024, including the appointment of a new Chief Operating Officer, Chief Revenue Officer, Senior Vice President of Operations, and President of Regulatory Strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
News

Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. A conference call will be hosted by management at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast or access the call through dial-in or webcast replay on the investor relations page of the Simulations Plus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
earnings
-
News

Simulations Plus Outlines Paths to Win at 2023 Investor Day

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) to Host Virtual Investor Day, Reiterates 2024 Guidance. CEO Shawn O’Connor highlights the client-centric business model and new organizational structure driving growth and innovation. Fiscal 2024 guidance includes a 10-15% revenue increase and 35-39% annual increase in diluted earnings per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
none
News

ISoP New Board of Trustees Members Announced

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces Amparo de la Peña, Vice President of Pharmacometrics, elected to the International Society of Pharmacometrics (ISoP) Board of Trustees. Three other Trustees also elected. Jill Fiedler-Kelly, President of Clinical Pharmacology & Pharmacometrics at Simulations Plus, praises Amparo's experience and leadership qualities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none

FAQ

What is the current stock price of Simulations Plus (SLP)?

The current stock price of Simulations Plus (SLP) is $33.5 as of January 23, 2025.

What is the market cap of Simulations Plus (SLP)?

The market cap of Simulations Plus (SLP) is approximately 651.3M.

What does Simulations Plus, Inc. do?

Simulations Plus develops modeling and simulation software and offers consulting services for drug discovery and development.

What are the main products of Simulations Plus?

Key products include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, and PKPlus™.

How does Simulations Plus support drug development?

The company provides data-driven modeling methodologies from early discovery through clinical trials and post-approval.

Who uses Simulations Plus technology?

Pharmaceutical companies and regulatory agencies worldwide utilize their technology.

What are the primary segments of Simulations Plus’ operations?

The primary segments are software and services.

Which subsidiaries are part of Simulations Plus?

Cognigen Corporation and DILIsym Services are subsidiaries of Simulations Plus.

How long has Simulations Plus been in operation?

The company has been in operation for over 20 years.

Where is Simulations Plus headquartered?

The company is headquartered in Lancaster, California.

Does Simulations Plus offer consulting services?

Yes, the company provides consulting and contract research services to the pharmaceutical industry.

How can I stay updated on Simulations Plus’ latest news?

You can visit the news section on their website to stay updated with the latest developments and achievements.
Stock SLP logo
Simulations Plus, Inc.

Nasdaq:SLP

SLP Rankings

#2898 Ranked by Market Cap
#1930 Ranked by Dividends

SLP Stock Data

651.30M
16.49M
18.03%
77.84%
4.97%
Health Information Services
Services-computer Integrated Systems Design
Link
United States of America
RESEARCH TRIANGLE PARK